Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

GPR31 Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Validation of the GPR31 Receptor in transfected HEK293 cells
GPR31 (non-phospho), G protein-coupled...
The non-phospho-GPR31 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human GPR31. It can be used to detect total GPR3 receptors in Western blots independent of phosphorylation. The GPR31 antibody...
$ 375.00 *
Details

GPR31 (G Protein-Coupled Receptor 31) is an orphan GPCR that has been identified as a receptor for 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE), a lipid metabolite involved in inflammatory and cancer-related processes. Upon binding to 12(S)-HETE, GPR31 activates intracellular signaling pathways associated with cell migration, survival, and proliferation. GPR31 is expressed in a variety of tissues, including prostate, colon, and pancreatic tissues, as well as in certain immune cells and endothelial cells. It is particularly upregulated in several cancer types, such as pancreatic ductal adenocarcinoma and colorectal cancer.GPR31 is considered a potential pharmacological target, especially in cancer biology, due to its role in promoting tumor cell invasion and survival through 12(S)-HETE signaling. Although drug development targeting GPR31 is still in the early stages, it is being studied for its involvement in tumor progression, angiogenesis, and inflammation, making it a candidate for future oncology and immunomodulatory therapies. For more information on GPR31 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

GPR31 (G Protein-Coupled Receptor 31) is an orphan GPCR that has been identified as a receptor for 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE), a lipid metabolite involved in inflammatory and... read more »
Close window
GPR31 Receptor Antibodies

GPR31 (G Protein-Coupled Receptor 31) is an orphan GPCR that has been identified as a receptor for 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE), a lipid metabolite involved in inflammatory and cancer-related processes. Upon binding to 12(S)-HETE, GPR31 activates intracellular signaling pathways associated with cell migration, survival, and proliferation. GPR31 is expressed in a variety of tissues, including prostate, colon, and pancreatic tissues, as well as in certain immune cells and endothelial cells. It is particularly upregulated in several cancer types, such as pancreatic ductal adenocarcinoma and colorectal cancer.GPR31 is considered a potential pharmacological target, especially in cancer biology, due to its role in promoting tumor cell invasion and survival through 12(S)-HETE signaling. Although drug development targeting GPR31 is still in the early stages, it is being studied for its involvement in tumor progression, angiogenesis, and inflammation, making it a candidate for future oncology and immunomodulatory therapies. For more information on GPR31 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

Recently viewed